LAVA Therapeutics Receives 87% Tender Offer for Acquisition by XOMA Royalty.

LAVA Therapeutics announced that 87% of its outstanding shares, or 22.9 million shares, were tendered in XOMA Royalty's acquisition offer. The minimum tender condition and other conditions have been met, and the shares are expected to be accepted for payment on November 13, 2025. The subsequent offering period has commenced and will end on November 20, 2025.